Novartis AG Stock News

Novartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.

Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results.

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo

Bristol Myers Squibb is turning on its innovative machine to get through recent patent cliffs. Novartis recently became a thinner company that is laser-focused on developing new medicines.

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 millio

Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.

Novartis said on Thursday that its tender offer for MorphoSys has begun, with an offer price of 68 euros ($73.08) per share in cash, corresponding to a premium of 142% on the volume-weighted average p

Novartis (NYSE: NVS ) layoffs are in the news Wednesday after the healthcare company announced plans to cut jobs in the U.S. and Switzerland. Starting with its U.S. jobs, the company intends to reduce

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday.

In the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the previous day.

Shares of Novartis (NVS) climbed Thursday as the pharmaceutical firm announced it would seek approval for expanded use of its cancer treatment, Pluvicto.